Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

CLOZAPINE FOR PEAK IDENTIFICATION CRS (0.41 MG)

CLOZAPINE FOR PEAK IDENTIFICATION CRS (0.41 MG)

5786-21-0

DISCOVER
TRIMIPRAMINE FOR PEAK IDENTIFICATION CRS (0.51 MG)

TRIMIPRAMINE FOR PEAK IDENTIFICATION CRS (0.51 MG)

521-78-8

DISCOVER
VINPOCETINE IMPURITY D CRS (15 MG)

VINPOCETINE IMPURITY D CRS (15 MG)

NA

DISCOVER
PHOLCODINE CRS - * NARC (10 MG)

PHOLCODINE CRS - * NARC (10 MG)

509-67-1

DISCOVER
FLUOROURACIL IMPURITY A CRS (15 MG)

FLUOROURACIL IMPURITY A CRS (15 MG)

67-52-7

DISCOVER
FLUOROURACIL IMPURITY B CRS (15 MG)

FLUOROURACIL IMPURITY B CRS (15 MG)

496-76-4

DISCOVER
FLUOROURACIL IMPURITY C CRS (20 MG)

FLUOROURACIL IMPURITY C CRS (20 MG)

66-22-8

DISCOVER
FLUOROURACIL IMPURITY F CRS (10 MG)

FLUOROURACIL IMPURITY F CRS (10 MG)

56177-80-1

DISCOVER
PHTHALIC ACID CRS (20 MG)

PHTHALIC ACID CRS (20 MG)

88-99-3

DISCOVER
RESORCINOL CRS (30 MG)

RESORCINOL CRS (30 MG)

108-46-3

DISCOVER
Etodolac for peak identification CRS, 0.41mg

Etodolac for peak identification CRS, 0.41mg

41340-25-4

DISCOVER
PROMETHAZINE IMPURITY D CRS (35 MG)

PROMETHAZINE IMPURITY D CRS (35 MG)

NA

DISCOVER